ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1085

Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis

Peter C. Grayson1, Carmelo Carmona-Rivera2, Meryl Waldman3, Karran Phillips4, Venkataraman Subramaniam5, Paul Thompson6, Jonathan D. Graf7 and Mariana J. Kaplan1, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, 3NIDDK, National Institutes of Health, Bethesda, MD, 4NIDA, National Institutes of Health, Baltimore, MD, 5Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, 6Biochemistry and Molecular Pharmacology, University of Masshachussetts, Worcester, MA, 7Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cholinergic agonists, drug toxicity and vasculitis, Lupus, Neutrophil Extracellular Traps

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Levamisole, an anti-helminth drug, has been implicated in cases of drug-induced autoimmunity in humans exposed to adulterated cocaine. Clinical manifestations of levamisole-induced autoimmunity include cutaneous vasculitis and specific autoantibodies (e.g. anti neutrophil cytoplasmic antibodies, ANCA; antinuclear antibodies, ANA). Neutrophil extracellular trap (NET) formation is a novel cell death mechanism implicated in certain idiopathic autoimmune diseases.  Proteins commonly found within NETs include the specific targets of ANCA and ANA. The objective of this study was to determine the role of NET formation in the pathogenesis of levamisole-induced autoimmunity.

Methods: Human and mouse neutrophils were exposed to graded concentrations of levamisole.  NET formation was visualized and quantified by fluorescence microscopy.  To assess the pathways involved in levamisole-induced NETosis, in some experiments the following inhibitors were added diphenylene iodonium (DPI), an inhibitor of reactive oxygen species, and Cl-amidine, an inhibitor of peptidylarginine deiminase (PAD) enzymes. Involvement of Akt and Raf-MEK-ERK kinase pathways was tested by Western blot. The role of Toll-like receptors (TLRs) and muscarinic receptors (MR) in levamisole-induced NETosis was investigated. Pharmacologic inhibitors and MR knockout mice were used to study specific MR subtypes implicated in NETosis. MR subtype receptors on neutrophils from patient samples were assessed by flow cytometry. Autoantibodies against specific NET-components were examined among cocaine users with no overt sign of autoimmune disease. 

Results: Levamisole induced prominent NETs in human and murine neutrophils that contained myeloperoxidase and proteinase 3, the targets of ANCA.  NET formation induced by levamisole was dependent on phosphorylation of Akt and Raf-MEK-ERK kinase pathways.  DPI and Cl-amidine significantly abrogated levamisole-induced NETosis, highlighting that levamisole stimulates NETs via generation of reactive oxygen species and activation of PAD enzymes.  Both levamisole and acetylcholine induced NETs through MR engagement on the surface of neutrophils and not through stimulation of TLRs.  Atropine, a non-selective MR antagonist, blocked levamisole mediated NETosis. Screening experiments with pharmacologic inhibitors and neutrophils from MR knockout mice demonstrated that levamisole-induced NETosis was mediated through engagement of M3 muscarinic receptor. In a cohort of 21 patients actively using cocaine, 100% had quantifiable levamisole in urine, and sera from these patients demonstrated novel autoantibodies against NET components. In longitudinal observations, ex-vivo spontaneous NET formation correlated with periods of active cocaine use. 

Conclusion: Levamisole induces NETosis through engagement of M3 muscarinic receptors on the surface of neutrophils.  These findings implicate a novel interaction between the cholinergic nervous system and innate immunity in the pathogenesis of levamisole-induced autoimmunity.


Disclosure: P. C. Grayson, None; C. Carmona-Rivera, None; M. Waldman, None; K. Phillips, None; V. Subramaniam, None; P. Thompson, None; J. D. Graf, None; M. J. Kaplan, None.

To cite this abstract in AMA style:

Grayson PC, Carmona-Rivera C, Waldman M, Phillips K, Subramaniam V, Thompson P, Graf JD, Kaplan MJ. Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/levamisole-triggers-neutrophil-extracellular-trap-formation-through-muscarinic-receptors-in-patients-with-drug-induced-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levamisole-triggers-neutrophil-extracellular-trap-formation-through-muscarinic-receptors-in-patients-with-drug-induced-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology